Compliance officers in the pharmaceutical industry have a few new clues to consider from a top voice at the Securities and Exchange Commission about violations of the Foreign Corrupt Practices Act, and how to avoid them.
In remarks at a recent pharmaceutical industry conference, SEC Director of Enforcement Andrew Ceresney described FCPA enforcement in the pharma sector as a high priority. “Our FCPA focus obviously covers many industries,” Ceresney said. “But the pharma industry is one on which we have been particularly focused in recent years.”
